News
STAA
17.58
+2.99%
0.51
Staar Surgical Announces Chief Legal Officer Transition Plan
TipRanks · 3d ago
STAAR SURGICAL CO - AGREEMENT PROVIDES FOR SISITSKY'S TERMINATION OF EMPLOYMENT, EFFECTIVE AS OF FEBRUARY 4
Reuters · 3d ago
STAAR Surgical Company gewährt ausgeschiedenem Rechtschef zwölf Monate Gehalt und Bonus
Reuters · 3d ago
STAAR Surgical Grants Severance and Bonus Package to Departing Chief Legal Officer
Reuters · 3d ago
Staar Surgical Price Target Announced at $26.00/Share by Wedbush
Dow Jones · 5d ago
Wedbush Initiates Coverage On Staar Surgical with Neutral Rating, Announces Price Target of $26
Benzinga · 5d ago
Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
TipRanks · 5d ago
Staar Surgical (STAA) Initiated with a Hold at Wedbush
TipRanks · 5d ago
Staar Surgical initiated with a Neutral at Wedbush
TipRanks · 5d ago
Staar Taps Two Executives as Co-CEOs While Searching for Permanent Successor
Dow Jones · 6d ago
Why STAAR Surgical (STAA) Stock Is Trading Lower Today
Barchart · 6d ago
Staar Surgical Names Interim Co-CEOs Amid Leadership Transition
TipRanks · 6d ago
STAAR Surgical Names CFO And COO As Its Interim Co-CEOs
NASDAQ · 6d ago
STAAR Surgical Appoints Warren Foust And Deborah Andrews As Interim Co-CEOs, Effective Immediately
Benzinga · 6d ago
Staar Surgical appoints COO Warren Foust, CFO Deborah Andrews as interim co-CEOs
TipRanks · 6d ago
STAAR Surgical Names Warren Foust and Deborah Andrews Interim Co-CEOs
Reuters · 6d ago
*Staar Surgical: Committee Has Begun Search for New CEO >STAA
Dow Jones · 6d ago
STAAR SURGICAL APPOINTS WARREN FOUST AND DEBORAH ANDREWS INTERIM CO-CEOS
Reuters · 6d ago
*STAAR Surgical Appoints Warren Foust, Deborah Andrews Interim Co-CEOs >STAA
Dow Jones · 6d ago
*Staar Surgical: Apppointments Effecitve Feb. 1 >STAA
Dow Jones · 6d ago
More
Webull provides a variety of real-time STAA stock news. You can receive the latest news about Staar Surg through multiple platforms. This information may help you make smarter investment decisions.
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.